Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Taiwan Meiji Pharma
Taipei City, Taiwan
- Ownership
- Private
- Development stage
- Other
01
Overview
Taiwan Meiji Pharma is a new pharma subsidiary (established Dec 2024) aiming for launch in 2025, starting with belumosudil (REZUROCK) for chronic GVHD (pending TFDA approval), and pipelines of antibiotics and vaccines to strengthen infectious disease treatment in Taiwan. No clinical trial readouts available for Taiwan-specific programs yet.
- Therapeutic areas
- ImmunologyPsychiatry
- Modalities
- Small moleculeVaccineBiologic
- Industry
- Biotech
Beyond the preview
Go deeper on Taiwan Meiji Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Taiwan Meiji Pharma.